5 results
Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
Primary objective(s): To assess the effect of LysaKare® administration on serum potassium concentration in GEP-NET patients eligible for Lutathera® treatmentSecondary objective(s): To confirm the safety profile of LysaKare® infusion in GEP-NET…
Elinzanetant is an investigational compound. It is not approved for sale. That means it can only be used in studies like this one. Elinzanetant has been extensively tested in the laboratory. It has also been already administered to approximately 300…